Indication

Cerebrotendinous xanthomatosis

Cerebrotendinous xanthomatosis is a rare autosomal recessive lipid storage disorder of bile acid synthesis caused by pathogenic variants in the *CYP27A1* gene. Read more about Cerebrotendinous xanthomatosis

2 drugs 2 manufacturers

Advertisement

Drugs that treat it

Common Cerebrotendinous xanthomatosis therapies.

Showing 1–2 of 2 drugs

CTEXLI (chenodiol)

GALLSTONE SOLUBILIZING AGENTS·CEREBROTENDINOUS XANTHOMATOSIS
MIRUM PHARMACEU
Filter & compare in the drug finder →Opens the drug finder with Cerebrotendinous xanthomatosis preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Cerebrotendinous xanthomatosis.

Cerebrotendinous xanthomatosis is a rare autosomal recessive lipid storage disorder of bile acid synthesis caused by pathogenic variants in the *CYP27A1* gene.

This genetic defect leads to a deficiency in the mitochondrial enzyme sterol 27-hydroxylase, impairing primary bile acid production and driving systemic accumulation of cholestanol and cholesterol.

The disease primarily affects the central nervous system, eyes, gastrointestinal tract, and musculoskeletal structures, classically manifesting with infantile-onset chronic diarrhea, juvenile-onset bilateral cataracts, and tendon xanthomas typically involving the Achilles tendon.

Progressive pathophysiologic accumulation leads to severe adult-onset neurologic deterioration, characterized by ataxia, spasticity, peripheral neuropathy, dystonia, psychiatric disturbances, and cognitive decline.

Personalize your experience

Follow Cerebrotendinous xanthomatosis and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it